A group of 38 male recurrent idiopathic calcium stone formers were treated with oral supplements of orthophosphate (1 g phosphorus extra in the diet per day) and followed at intervals up to 4 years. The urinary excretion of calcium decreased (p < 0.001) and that of inorganic phosphate increased (p < 0.001) during treatment. These changes resulted in a small decrease in the supersaturation of urine with respect to calcium oxalate, sufficient to reduce the percentage of urines which exceeded the upper limit of solubility of that salt, and a small increase in the supersaturation of urine with respect to calcium phosphate. The stone episode rate on treatment fell in 35 of the 38 patients from a mean pretreatment value of 0.66 episodes/year to 0.22 episodes/year. The 3 initially most prolific stone formers increased their rate of stone formation during treatment. Plasma biochemistry showed no evidence of parathyroid stimulation.

Keywords:
Calcium stone disease, Urinary calcium, Urinary oxalate, Urinary supersaturation, Orthophosphate supplements, Stone recurrence
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.